- RDEA119 Produced Significant Beneficial Effect in Animal Models of
- RDEA594 Shows Promise as an Effective Treatment for Gout -
SAN DIEGO, June 11 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data will be presented on the Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, demonstrating its potent activity in animal models of arthritis. In addition, the Company will present data on the mechanism of action for RDEA806 and RDEA594 in the area of gout. These data will be presented tomorrow at the 2008 Annual European Congress of Rheumatology Organized by the European League Against Rheumatism (EULAR) in Paris, France.
The extracellular signal-regulated kinase (ERK) pathway plays a
critical role in the control of cellular activation, proliferation and the
production of inflammatory mediators. Suppression of the ERK pathway by
inhibitors of MEK1/2 represents a potential therapeutic approach for
treating chronic inflammatory diseases such as rheumatoid arthritis.
RDEA119 is a novel selective MEK1/2 inhibitor that was shown to produce a
significant beneficial effect in three different animal models of
-- Significantly reduced paw swelling in a dose-dependent manner in the
carrageenan-induced paw edema model in rats;
-- Virtually complete reduction in ankle swelling in the adjuvant-induced
arthritis model in rats;
-- Reduced arthritic scores by up to 82% in the collagen antibody-induced
arthritis model in mice.
"We are making excellent progress in all of our inflammation programs.
To support the development of RDEA119 in inflammatory diseases, we a
|SOURCE Ardea Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved